Open access
Open access
Powered by Google Translator Translator

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

15 Jun, 2021 | 09:12h | UTC

Press release: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

Commentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox

 

Commentary on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

No spam, just news.